Immunogenic compositions comprising progastrin and uses thereof
AssigneeBoard of Regents, The University of Texas System
InventorsPomila Singh, Gurpreet Singh
Life of this patent
Estimating the term…
Abstract
The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.
Claims13
A method of treating colorectal cancer in a human comprising:
- administering to a human subject suffering from colorectal cancer a composition comprising a pharmaceutically effective amount of an antibody that specifically binds human progastrin, wherein the antibody blocks binding of human progastrin to an Annexin II receptor, wherein the antibody inhibits the growth-inducing activity of progastrin in the cell, and wherein the antibody is monoclonal or polyclonal made by immunizing with full length recombinant human progastrin.
A method of treating a colorectal cancer, a pancreatic cancer, or a gastrointestinal cancer in a human comprising:
- administering to a human subject suffering from colorectal cancer, pancreatic cancer, or gastrointestinal cancer a composition comprising a pharmaceutically effective amount of an agent targeting human progastrin, wherein the agent is an antibody that specifically binds human progastrin or a fragment thereof, wherein the antibody results in blocking binding of human progastrin to an Annexin II receptor, wherein the antibody inhibits the growth-inducing activity of progastrin in the cell, and wherein the antibody is monoclonal or polyclonal made by immunizing with full length recombinant human progastrin.
Dependencies are inferred from the claim text.